Capacity Expansions

Preparing for Organic Growth and Resilience

The biopharma market is the fastest-growing pharmaceutical segment. Against this backdrop, we have been investing significantly in the expansion of our production capacities in all geographies – the Americas, Europe, and Asia. We are expanding our global presence with customers by setting up Customer Interaction Centers, and we are investing in a substantial expansion of our activities in South Korea.

In addition to preparing our production and research infrastructure for organic growth, we have also invested in resilience in the face of geopolitical uncertainties, with the goal of continuing to meet the highest standards for delivery reliability and product quality in all regions.

Sartorius expands manufacturing and R&D capacities in France

June 17, 2025 - Sartorius today celebrates the completion of a multi-year capacity expansion project at the headquarters of its French sub-group Sarto...

Read Media Release

€410 million worldwide investment in 2024

Interactive Map: Preparing for Organic Growth and Resilience

Discover the Locations

Ann Arbor, USA

Yauco, Puerto Rico, USA

Marlborough, USA

Göttingen, Germany

Aubagne, France

Freiburg, Germany

Ulm, Germany

M'Hamdia, Tunisia

Ajdovscina, Slovenia

Beit Haemek, Israel

Havant, UK

Songdo, South Korea

Beijing, China

Shanghai, China

Increase of Capacities for Key Products

Separation

Sartorius' extensive filtration and purification portfolio helps you overcome your major challenges.

Fluid Management

With over 20 years of experience in manufacturing reliable, economical and safe solutions, we are your best partner for manufacturing facilities.

Instruments & Systems

Sartorius offers complete scalable bioreactor platforms from cell and strain line development to commercial manufacturing.

We share our customer's mission to develop life-changing therapies.

Accelerate commercialization with end-to-end solutions that deliver performance, scalability, and a simplified path to regulatory approvals.

Explore Our Portfolio

Local Contact

Investor Relations

Newsroom